Molecular mechanisms of sorafenib action in liver cancer cells

Abstract excerpt

Sorafenib, a multikinase inhibitor, recently received FDA approval for the treatment of advanced hepatocellular carcinoma (HCC). However, as the clinical application of sorafenib evolves, there is increasing interest in defining the mechanisms underlying its anti-tumor activity. Considering that this specific inhibitor could target unexpected molecules depending on the biologic context, a precise understanding of...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Cancer Mechanisms and Therapy
• Share to Hepatocellular Carcinoma Treatment and Prognosis
• Share to PI3K/AKT/mTOR signaling in cancer